摘要 |
<p>The present invention relates to an improved process for preparing (2R,3aR,10Z,11aS,2aR,14aR)-cyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxylic acid, 2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydro-2-[[7-methoxy-8-methyl-2-[4-10(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5-methyl-4,14-dioxo-, ethyl ester. This compound is an intermediate in the overall synthesis route of the macrocyclic compound TMC 435. TMC 435 is an inhibitor of NS3/4A protease which plays an important role in the replication of the hepatitis C virus.</p> |
申请人 |
JANSSEN PHARMACEUTICALS INC |
发明人 |
HORVATH, ANDRAS;WUYTS, STIJN;DEPR, DOMINIQUE PAUL MICHEL;COUCK, WOUTER LOUIS J;CUYPERS, JOZEF LUDO JAN;HARUTYUNYAN, SYUZANNA;BINOT, GREGORY FABIEN SEBASTIEN |